Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $38.50.

A number of equities analysts have commented on the company. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Wells Fargo & Company lifted their price target on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price for the company. Finally, Guggenheim upped their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th.

Insider Buying and Selling

In other news, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider directly owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. The trade was a 5.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Tia L. Bush sold 40,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. The trade was a 24.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC lifted its stake in Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Centessa Pharmaceuticals by 20.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after purchasing an additional 1,449,000 shares during the last quarter. Commodore Capital LP raised its holdings in Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after purchasing an additional 930,711 shares in the last quarter. TCG Crossover Management LLC lifted its position in shares of Centessa Pharmaceuticals by 8.5% during the 3rd quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock worth $76,060,000 after buying an additional 245,664 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 0.6% in the 3rd quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock valued at $62,042,000 after buying an additional 14,875 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $24.57 on Friday. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The stock has a market cap of $3.30 billion, a P/E ratio of -13.43 and a beta of 1.56. The firm has a fifty day moving average price of $25.56 and a 200 day moving average price of $22.42.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.